X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New data show how insurers and middlemen shift Rx costs onto patients

By Brian Newell  |    November 16, 2022
There is only one place in the health care system where middlemen refuse to share negotiated prices with patients, and that’s at the pharmacy counter. A new report reveals how this harmful tactic...   Read More

Busting 3 Myths About Copay Coupons

By Katie Koziara  |    October 5, 2022
Insurer-imposed barriers like high deductibles and coinsurance shift the cost of life-saving care onto patients. Manufacturers and others have stepped forward to assist patients who face high...   Read More

Making coupons count for patients at the pharmacy counter

By Katie Koziara  |    August 25, 2022
Too many patients face high out-of-pocket costs for brand medicines, even when they have insurance.   Read More

By the Numbers: Patients lose when the government sets prices

By Nicole Longo  |    July 8, 2022
Yet again, Congress is considering harmful drug pricing policies with complete disregard for the negative impact they will have on patients and our economy. At the same time, they are continuing to...   Read More

Prescription drug prices are not fueling inflation

By Sarah Sutton  |    July 6, 2022
Inflation is causing pain for people across the country. As policymakers search for ways to help provide relief, some are erroneously tying inflation to prescription medicines. To make matters worse,...   Read More

In comments to federal agency, PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for prescription medicines

By Brian Newell  |    May 31, 2022
In comments submitted to the Federal Trade Commission (FTC), PhRMA urged the agency to examine how pharmacy benefit managers (PBMs) leverage their extraordinary power to maximize profits, often in...   Read More

Report finds PBMs are increasingly restricting patient access to medicines

By Brian Newell  |    May 25, 2022
More than 1,150 medicines were excluded from at least one of the three largest PBMs’ standard commercial formularies in 2022, according to a new report from Xcenda. The report is further evidence of...   Read More

ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

By Andrew Powaleny  |    May 13, 2022
This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to...   Read More

Annual projections from NHE compared to actual health care spending

By Katie Koziara  |    May 5, 2022
The Centers for Medicare & Medicaid Services (CMS) recently released their National Health Expenditure (NHE) projections of health care spending in the United States through 2030. While these data...   Read More

What’s really happening when it comes to prescription drug costs

By Katie Koziara  |    April 27, 2022
New data show how robust competition continues to keep national spending on life-saving medicines in check, even as new innovative treatments reach patients. According to the latest report by the...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates